This federal contract award is for the delivery of HETLIOZ (tasimelteon), a pharmaceutical product, to the U.S. Department of Veterans Affairs (VA). The contract was awarded to the prime contractor, Vanda Pharmaceuticals Inc., doing business as Vanda, on October 1, 2024. The contract has a ceiling value of $162,771.05 and a performance period extending through September 30, 2025. This award is a delivery order placed against Vanda's existing GSA Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract is not designated as a set-aside. Vanda is the sole manufacturer of HETLIOZ, a medication used to treat Non-24-Hour Sleep-Wake Disorder in blind adults and patients with Smith-Magenis Syndrome. This contract supports the VA's efforts to provide specialized pharmaceutical products to eligible veterans, addressing their unique medical needs. In addition to this delivery order, Vanda holds a significant Blanket Purchase Agreement (BPA) with the VA National Acquisition Center, further demonstrating the VA's reliance on Vanda as a key supplier of HETLIOZ.
Generated 10/2/24, 11:03 AM